Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study

BACKGROUND: Combination of the inhaled long-acting muscarinic antagonist umeclidinium (UMEC; GSK573719) with the long-acting β(2)-agonist vilanterol (VI) is an approved maintenance treatment for COPD in the US and EU. We compared the efficacy and safety of UMEC/VI with placebo in patients with COPD...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Jinping, Zhong, Nanshan, Newlands, Amy, Church, Alison, Goh, Aik H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562726/
https://www.ncbi.nlm.nih.gov/pubmed/26366068
http://dx.doi.org/10.2147/COPD.S81053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562726/
https://www.ncbi.nlm.nih.gov/pubmed/26366068
http://dx.doi.org/10.2147/COPD.S81053

Ejemplares similares